OCOcugen OCGN · NASDAQ
$0.80 -1.71% (-$0.01)
- Market cap
- $275.9M
- Enterprise value
- $263.9M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 60.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -92.7%
- Gross margin
- 100.0%
- Net margin
- -1,786.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.27
- Free float
- 97.5%
About the company
Ocugen (OCGN) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products. Its primary goal is to provide patients with high therapeutic value medicines and contribute to improving their health outcomes. The company specializes in the treatment of ocular diseases, including rare eye disorders. Ocugen stock is suitable for investors interested in the biotechnology sector and those who want to support innovative treatment approaches. Add Ocugen stock to your watchlist on Bulios and gain access to the latest information about this company that is pushing the boundaries of ocular disease management.
Sector
Healthcare
Industry
Biotechnology
CEO
Shankar Musunuri
Employees
116
Headquarters
Malvern
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number